Dual Mechanisms of Morin in Bioavailability Potentiation and Hepatoprotection: Enhancing Enrofloxacin Safety in Poultry through ABC Transporter Inhibition and Antioxidant Pathway Activation.

Morin enhances enrofloxacin bioavailability and prevents liver injury in poultry.

This study investigates morin, a flavonoid compound, as a dual-functional oral enhancer for enrofloxacin in poultry. The research addresses the critical issue of low antibiotic bioavailability mediated by ABC transporters, which contributes to antimicrobial resistance (AMR). Using chicken hepatocyte models and in vivo poultry studies, researchers demonstrated that morin at 60 mg/kg significantly increased enrofloxacin oral bioavailability from 62.16% to 91.04% through direct ABC transporter inhibition and downregulation of xenobiotic receptor (CXR)-mediated transporter expression. Notably, morin avoided the hepatotoxicity associated with traditional ABC inhibitors like verapamil and cyclosporine A. Additionally, morin provided hepatoprotection against enrofloxacin-induced liver injury through activation of the Nrf2-mediated antioxidant pathway and suppression of NF-κB-mediated inflammatory responses. These findings suggest morin represents a promising strategy to enhance antibiotic efficacy while maintaining drug safety in poultry production, potentially reducing AMR transmission while mitigating drug-induced hepatotoxicity.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.